Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.


Imoukhuede, EB; Berthoud, T; Milligan, P; Bojang, K; Ismaili, J; Keating, S; Nwakanma, D; Keita, S; Njie, F; Sowe, M; Todryk, S; Laidlaw, SM; Skinner, MA; Lang, T; Gilbert, S; Greenwood, BM; Hill, AV; (2006) Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine, 24 (42-43). pp. 6526-33. ISSN 0264-410X DOI: https://doi.org/10.1016/j.vaccine.2006.06.022

Full text not available from this repository.

Abstract

We assessed the safety and immunogenicity of prime-boost vectors encoding the Plasmodium falciparum circumsporozoite (CS) protein expressed either in the attenuated fowl-pox virus (FP9) or modified vaccinia virus Ankara (MVA). Thirty-two adult Gambians in groups of four to eight received one, two or three doses of FP9 CS and/or MVA CS. No serious adverse event was observed following vaccination. The most immunogenic regimen was two doses of FP9 followed by a single dose of MVA 4 weeks later (an average of 1000 IFN-gamma spot forming units/million PBMCs). This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Research Centre: Malaria Centre
Tropical Epidemiology Group
PubMed ID: 16842888
Web of Science ID: 241846700009
URI: http://researchonline.lshtm.ac.uk/id/eprint/11712

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
328Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item